Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Cash & Equivalents (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Cash & Equivalents for 12 consecutive years, with $167.8 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 343.97% to $167.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $167.8 million through Dec 2025, up 343.97% year-over-year, with the annual reading at $167.8 million for FY2025, 343.97% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $167.8 million at Theravance Biopharma, down from $174.8 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $418.5 million in Q3 2022, with the low at $23.4 million in Q3 2024.
  • Average Cash & Equivalents over 5 years is $136.5 million, with a median of $108.1 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents tumbled 86.74% in 2023, then skyrocketed 647.6% in 2025.
  • Over 5 years, Cash & Equivalents stood at $90.0 million in 2021, then soared by 231.45% to $298.2 million in 2022, then crashed by 86.74% to $39.5 million in 2023, then dropped by 4.42% to $37.8 million in 2024, then surged by 343.97% to $167.8 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $167.8 million, $174.8 million, and $281.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.